Lysosomal Acid Liapse (LAL) Deficiency Treatment Market, By Treatment (ERT, Stem Cell Therapy, Lipid Modifying Agents, Supportive Care, Surgery), By Indication (CESD, Wolman Disease), and By Geography (NA, EU, APAC, LATAM and MEA) Analysis, Share, Trends, Size, & Forecast From 2020 2026
- Published Date: 2020-10-13
- Report ID: 1794
- Pages: 158
-
Format:
REPORT HIGHLIGHT
Lysosomal Acid Liapse (LAL) Deficiency Treatment market was valued at USD 390.5 million by 2019, growing with 9.9% CAGR during the forecast period, 2020-2026
Market Dynamics
The growing adoption of enzyme replacement therapy for treatment is one of the major factors driving the growth of global lysosomal acid lipase deficiency (LAL-D) treatment market. In addition, large patient pool and high prevalence of lysosomal acid lipase deficiency are other factors boosting the market growth. LAL-D is a rare type of lysosomal storage disorder, wherein patients are not able to triglycerides and cholesteryl esters due to a mutation in the lysosomal acid lipase gene. Thus, there is an accumulation of lipids in the walls of blood vessels, spleen, and liver. LAL-D is a progressive disease with early mortality due to liver failure, medical complications, and multi-systemic clinical manifestations. Moreover, governments of both developed and developing countries are taking the initiative to make people aware of the LAL-D treatment. Also, pharmaceutical companies are investing more in research and development to provide better treatment for patients. This is anticipated to create lucrative opportunities in the global industry during the forecast period. However, high costs associated with treatment and lack of awareness amongst individuals regarding LAL-D treatment are predicted to hamper the market growth in the coming future.
The current management of LAL-D is majorly focused on nutritional support and nutritional care. The supportive care segment dominated the global market in 2018 mainly because it includes high triglycerides and cholesterol through lipid-lowering statins, low-fat diet, apolipoprotein B production, and management of plasma lipid levels. Along with supportive care, the enzyme replacement therapy (ERT) segment is estimated to grow at the fastest CAGR during the forecast period. This rapid growth is majorly due to high efficiency and long-term disease control post-treatment.
Treatment Takeaway
The cholesteryl ester storage disease (CESD) segment is anticipated to witness the fastest growth during the forecast period. This rapid growth is majorly due to the increasing uptake of ERT and high disease prevalence. In addition, the CSED has a higher prevalence rate than the Wolman disease. On the other hand, the Wolman disease is considered to be of the more severe form, which has an early onset. It occurs due to non-existence of lysosomal acid lipase enzyme activity. There are no clinical signs shown by infants at the time of birth, but after a few months suffer from vomiting, diarrhoea, jaundice, and develop enlarged spleens and livers.
Regional Takeaway
The North America region dominated the global LAL-D treatment market in 2018 followed by Europe. North America is poised to lead the market by the end of 2030 owing to the presence of a large patient pool and high disease prevalence. Europe region is estimated to be the second-largest market owing to the growing occurrence of disease and rising uptake of Kanuma.
Key Vendors Takeaway
Limited therapeutic intervention for LAL-D and increasing eligible patient population is expected to offer a strong commercial opportunity to major industry players to invest in the development of novel treatments in the global market.
Key players of the market include:
Alexion Pharmaceutical Inc.
Merck & Co., Inc.
AstraZeneca plc.
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year 2015 to 2018
Base Year 2019
Estimated Year 2020
Projected Year 2026
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY TREATMENT
Lipid Modifying Agents (Statins)
Enzyme Replacement Therapy (ERT)
Stem Cell Therapy
Supportive Care
Surgery
GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY INDICATION
Cholesteryl Ester Storage Disease (CESD)
Wolman Disease (WD)
Others
GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY REGION
North America
o The U.S.
o Canada
Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA
TABLE OF CONTENT
1. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Treatment
2.1.2. Market Snippet by Indication
2.1.3. Market Snippet by Region
2.2. Competitive Insights
3. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT INDUSTRY STUDY
4.1. Porters Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
4.5. COVID-19 Impact Analysis
4.5.1. Pre-COVID-19 Impact Analysis
4.5.2. Post-COVID-19 Impact Analysis
5. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET LANDSCAPE
5.1. Market Share Analysis
5.2. Key Innovators
5.3. Breakdown Data, by Key manufacturer
5.3.1. Established Player Analysis
5.3.2. Emerging Player Analysis
6. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET BY TREATMENT
6.1. Overview
6.1.1. Segment Share Analysis, By Treatment, 2019 & 2026 (%)
6.2. Lipid Modifying Agents (Statins)
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
6.3. Enzyme Replacement Therapy (ERT)
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
6.4. Stem Cell Therapy
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
6.5. Supportive Care
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
6.6. Surgery
6.6.1. Overview
6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
7. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET BY INDICATION
7.1. Overview
7.1.1. Segment Share Analysis, By Indication, 2019 & 2026 (%)
7.2. Cholesteryl Ester Storage Disease (CESD)
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
7.3. Wolman Disease (WD)
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
7.4. Others
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8. LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
8.2. North America
8.2.1. Overview
8.2.2. Key Manufacturers in North America
8.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
8.2.4. North America Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
8.2.5. North America Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
8.2.6. U.S.
8.2.6.1. Overview
8.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.2.7. Canada
8.2.7.1. Overview
8.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.3. Europe
8.3.1. Overview
8.3.2. Key Manufacturers in Europe
8.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
8.3.4. Europe Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
8.3.5. Europe Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
8.3.6. Germany
8.3.6.1. Overview
8.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.3.7. Italy
8.3.7.1. Overview
8.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.3.8. United Kingdom
8.3.8.1. Overview
8.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.3.9. France
8.3.9.1. Overview
8.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.3.10. Rest of Europe
8.3.10.1. Overview
8.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.4. Asia Pacific (APAC)
8.4.1. Overview
8.4.2. Key Manufacturers in Asia Pacific
8.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
8.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
8.4.5. Asia Pacific Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
8.4.6. India
8.4.6.1. Overview
8.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.4.7. China
8.4.7.1. Overview
8.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.4.8. Japan
8.4.8.1. Overview
8.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.4.9. South Korea
8.4.9.1. Overview
8.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.4.10. Rest of APAC
8.4.10.1. Overview
8.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.5. Latin America
8.5.1. Overview
8.5.2. Key Manufacturers in Latin America
8.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
8.5.4. Latin America Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
8.5.5. Latin America Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
8.5.6. Brazil
8.5.6.1. Overview
8.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.5.7. Mexico
8.5.7.1. Overview
8.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.5.8. Argentina
8.5.8.1. Overview
8.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.5.9. Rest of LATAM
8.5.9.1. Overview
8.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.6. Middle East and Africa
8.6.1. Overview
8.6.2. Key Manufacturers in Middle East and Africa
8.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
8.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2015 - 2026 (US$ Million)
8.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2015 - 2026 (US$ Million)
8.6.6. Saudi Arabia
8.6.6.1. Overview
8.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
8.6.7. United Arab Emirates
8.6.7.1. Overview
8.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
9. KEY VENDOR ANALYSIS
9.1. AstraZeneca plc.
9.1.1. Company Snapshot
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. Alexion Pharmaceutical Inc.
9.3. Merck & Co., Inc.
9.4. Teva Pharmaceutical Industries Ltd.
9.5. Pfizer, Inc.
10. 360 DEGREE ANALYSTVIEW
11. APPENDIX
11.1. Research Methodology
11.2. References
11.3. Abbreviations
11.4. Disclaimer
11.5. Contact Us
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
